Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.

Find People
Find Research
Overview
Tutorials
FAQs
Edit My PROFILE
Login to PROFILES

History

A Retrospective Compar

Experiences of racism

Sugar-sweetened bevera

Barriers to participat

Quantitative Benefit-R

See All (19) pages

Contact Us
If you have any questions or feedback please contact us.

Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.

Yuan Z, Levitan B, Deng H, Szarek M, Bauersachs RM, Berkowitz SD, Haskell L, Barnathan ES, Bonaca MP. Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. J Am Heart Assoc. 2024 Apr 16; 13(8):e032782.

View in: PubMed

subject areas

Aspirin
Drug Therapy, Combination
Factor Xa Inhibitors
Hemorrhage
Humans
Myocardial Infarction
Peripheral Arterial Disease
Platelet Aggregation Inhibitors
Risk Assessment
Rivaroxaban

authors with profiles

Michael Jon Szarek
Marc Peter Bonaca
Scott Darrell Berkowitz

Contact Us
CCTSI
About CCTSI
CCTSI Affiliated Institutions
National CTSA Consortium